Physician profile
Ravi B Sutaria
NPI 1528357852
$52,431.36
in general payments reported to CMS, 2019-2025
36 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,818 · 2020: $3,640 · 2021: $10K · 2022: $2,968 · 2023: $3,928 · 2024: $5,239 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $7,450 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,700 · Travel and Lodging: $907 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,707.43 |
| Consulting Fee | $7,450.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,700.00 |
| Travel and Lodging | $906.64 |
| Education | $117.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $14,992.22 | 2020-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $13,062.67 | 2019-2023 | Krystexxa |
| Amgen INC. | $6,589.77 | 2019-2025 | Evenity, Krystexxa, Enbrel |
| Abbvie INC. | $6,258.80 | 2019-2025 | Rinvoq, Skyrizi |
| Glaxosmithkline, LLC. | $1,987.29 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $1,774.52 | 2019-2025 | |
| Lilly USA, LLC | $1,354.69 | 2020-2025 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,313.50 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $1,001.66 | 2020-2025 | Tremfya, Simponi Aria |
| Ani Pharmaceuticals, INC. | $814.17 | 2022-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $613.71 | 2019-2025 | Cyltezo, Ofev |
| Mallinckrodt Hospital Products INC. | $421.69 | 2020-2025 | Acthar |
| Pfizer INC. | $262.55 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $235.43 | 2020-2024 | Orencia |
| Genentech USA, INC. | $205.60 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $196.37 | 2019 | |
| Genentech, INC. | $159.80 | 2019 | |
| Radius Health, INC. | $157.06 | 2023-2025 | Tymlos |
| Cumberland Pharmaceuticals, INC. | $130.33 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $127.42 | 2021-2023 | Lupkynis |
| Janssen Scientific Affairs, LLC | $98.57 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.39 | 2019 | |
| Genzyme Corporation | $75.47 | 2023 | |
| Janssen Pharmaceuticals, INC | $69.49 | 2025 | Tremfya |
| Sobi, INC | $57.35 | 2024 | |
| Fidia Pharma USA INC. | $52.99 | 2022-2025 | Hymovis |
| Medexus Pharma, INC. | $52.32 | 2019-2020 | |
| Celgene Corporation | $44.52 | 2019 | |
| Depuy Synthes Sales INC. | $44.05 | 2019-2024 | Orthovisc |
| Ultragenyx Pharmaceutical INC. | $37.35 | 2022 | |
| Bioventus LLC | $30.86 | 2022-2024 | Gelsyn-3 |
| Alexion Pharmaceuticals, INC. | $28.85 | 2025 | Strensiq |
| Invivyd INC | $26.42 | 2025 | Pemgarda |
| Octapharma USA, INC. | $25.77 | 2025 | Octagam Immune Globulin (Human) |
| Hikma Pharmaceuticals USA | $15.93 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $14.78 | 2023 | Zilretta, Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Sutaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.